This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Five Prime Therapeutics, Inc.
Drug Names(s): FP1039, GSK 3052230, HGS1036, GSK3052230
Description: FP-1039 is a ligand trap that binds to and inhibits most members of the FGF (Fibroblast Growth Factor) family. FP-1039 is a soluble fusion protein consisting of the extracellular portion of Fibroblast Growth Factor Receptor 1 (FGFR1) that is attached to the base of a human antibody. The drug is designed to neutralize the activity of multiple FGF ligands and inhibit their signaling through all FGF receptors.
FivePrime and Human Genome Sciences
In March 2011, Human Genome Sciences (HGS) and FivePrime Therapeutics announced that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers. HGS paid FivePrime an upfront license fee of $50,000. HGS may be required to pay up to $445,000 in future development, regulatory and commercial milestone payments, as well as royalty payments on net sales if the product is commercialized. HGS has exclusive rights to develop and commercialize FP-1039 for all indications in the United States, Canada and the European Union (EU). FivePrime has an option to co-promote FP-1039 and any next-generation products in the United States, and retains full development and commercialization rights in all other regions of the world outside the US, Canada and the EU.
GlaxoSmithKline and Human Genome Sciences
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive...See full deal structure in Biomedtracker
Additional information available to subscribers only: